Skip to main content

Compare Stocks

Date Range: 

 IMVDecibel TherapeuticsEmblemNeptune Wellness SolutionsArix Bioscience
SymbolTSE:IMVNASDAQ:DBTXCVE:EMCTSE:NEPTLON:ARIX
Price Information
Current PriceC$2.80$6.76$1.88C$1.47GBX 182
52 Week RangeHoldBuyN/ABuyHold
MarketRank™
Overall Score1.21.80.51.20.8
Analysis Score3.04.50.03.50.0
Community Score2.84.52.52.52.3
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.00.0
Earnings & Valuation Score0.00.00.00.01.9
Analyst Ratings
Consensus RecommendationHoldBuyN/ABuyHold
Consensus Price TargetC$4.03$27.20N/AC$5.50N/A
% Upside from Price Target44.05% upside302.37% upsideN/A274.15% upsideN/A
Trade Information
Market CapC$190.51 million$162.61 million$248.31 millionC$248.24 million£244.03 million
BetaN/AN/AN/AN/AN/A
Average Volume141,348140,957865,800546,997267,984
Sales & Book Value
Annual RevenueC$20,385.00N/A$5.71 millionC$52.78 million£135.77 million
Price / Sales9,312.18N/A43.024.611.79
CashflowC$0.45 per shareN/A$0.46 per shareC$0.24 per shareGBX 132.87 per share
Price / Cash6.23N/A4.086.031.37
Book ValueC$0.39 per shareN/A$0.67 per shareC$0.92 per shareGBX 251.40 per share
Price / Book7.11N/A2.821.600.01
Profitability
Net IncomeN/AN/AN/AN/AN/A
EPSC($0.52)N/A($0.19)C($1.35)GBX 88.70
Trailing P/E RatioN/A0.00N/AN/A2.05
Forward P/E Ratio
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)N/AN/AN/AN/AN/A
Dividend
Annual PayoutN/AN/A$0.46N/AN/A
Dividend YieldN/AN/A24.47%N/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/A N/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio30.78%N/A30.01%3.75%0.08%
Current Ratio6.65%N/A3.61%4.01%78.63%
Quick Ratio5.85%N/A3.24%2.69%78.01%
Ownership Information
Institutional Ownership PercentageN/AN/AN/AN/AN/A
Insider Ownership PercentageN/AN/AN/AN/AN/A
Miscellaneous
Employees7740N/A16512
Shares Outstanding67.80 million24.90 million130.56 million165.49 million133.35 million
Next Earnings Date8/11/2021 (Estimated)8/12/2021 (Estimated)N/A6/8/2021 (Estimated)N/A
OptionableNot OptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
Arix Bioscience PLC: Notice of 2021 Annual General MeetingArix Bioscience PLC: Notice of 2021 Annual General Meeting
finanznachrichten.de - May 18 at 8:01 AM
Autolus to present additional data in AUTO1 in IBCLAutolus to present additional data in AUTO1 in IBCL
finanztreff.de - May 14 at 11:40 PM
Arix Bioscience PLC: Autolus to present additional data in AUTO1 in IBCLArix Bioscience PLC: Autolus to present additional data in AUTO1 in IBCL
finanznachrichten.de - May 12 at 1:33 PM
Acacia wins board changes at ex-Woodford stock Arix BioAcacia wins board changes at ex-Woodford stock Arix Bio
citywire.co.uk - May 5 at 1:27 PM
Amplyx Pharmaceuticals acquired by PfizerAmplyx Pharmaceuticals acquired by Pfizer
uk.finance.yahoo.com - April 30 at 2:35 PM
US buy-up firm advised by Neil Woodford takes control of British biotech investorUS buy-up firm advised by Neil Woodford takes control of British biotech investor
standard.co.uk - April 30 at 2:35 PM
Outcome of Strategic Implementation Review and Directorate ChangeOutcome of Strategic Implementation Review and Directorate Change
uk.finance.yahoo.com - April 30 at 4:34 AM
Arix Bioscience PLC: Outcome of Strategic Implementation Review and Directorate ChangeArix Bioscience PLC: Outcome of Strategic Implementation Review and Directorate Change
finanznachrichten.de - April 30 at 4:34 AM
Arix Bioscience concludes strategic review, reshuffles boardArix Bioscience concludes strategic review, reshuffles board
proactiveinvestors.co.uk - April 30 at 4:34 AM
CORRECT (Apr 27): Arix portfolio firm partners with Daiichi, CANbridgeCORRECT (Apr 27): Arix portfolio firm partners with Daiichi, CANbridge
lse.co.uk - April 28 at 10:21 AM
Arix Bioscience PLC: Amplyx Pharmaceuticals acquired by Pfizer -2-Arix Bioscience PLC: Amplyx Pharmaceuticals acquired by Pfizer -2-
finanznachrichten.de - April 28 at 10:21 AM
Arix Biosciences portfolio firm Amplyx snapped up by PfizerArix Bioscience's portfolio firm Amplyx snapped up by Pfizer
proactiveinvestors.co.uk - April 28 at 10:21 AM
Arix Bioscience (LON:ARIX) Stock Rating Reaffirmed by Shore CapitalArix Bioscience (LON:ARIX) Stock Rating Reaffirmed by Shore Capital
americanbankingnews.com - April 28 at 6:50 AM
Arix Bioscience PLC: LogicBio announces clinical and corporate updates -2-Arix Bioscience PLC: LogicBio announces clinical and corporate updates -2-
finanznachrichten.de - April 27 at 1:34 PM
Arix Bioscience investee LogicBio signs strategic collaboration with CANBridge PharmaArix Bioscience investee LogicBio signs strategic collaboration with CANBridge Pharma
proactiveinvestors.co.uk - April 27 at 1:34 PM
American investor seeks board changes at Arix BioscienceAmerican investor seeks board changes at Arix Bioscience
thetimes.co.uk - April 26 at 7:31 PM
Acacia looks to install its own directors in board shake-up of former Woodford biotech holdingAcacia looks to install its own directors in board shake-up of former Woodford biotech holding
portfolio-adviser.com - April 26 at 9:30 AM
Biotech group Arix prepares board shake-up in activist peace dealBiotech group Arix prepares board shake-up in activist peace deal
msn.com - April 22 at 1:15 PM
Biotech group Arix prepares board shake-up in peace deal with activist AcaciaBiotech group Arix prepares board shake-up in peace deal with activist Acacia
news.sky.com - April 22 at 1:15 PM
Arix Bioscience PLC : Arix to Present at the Proactive One2One Virtual Investor ForumArix Bioscience PLC : Arix to Present at the Proactive One2One Virtual Investor Forum
markets.businessinsider.com - April 17 at 12:11 AM
Shareholder broadside at biotech investor Arix’s boardShareholder broadside at biotech investor Arix’s board
uk.finance.yahoo.com - April 10 at 3:58 PM
Arix to Present at the Proactive One2One Virtual Investor ForumArix to Present at the Proactive One2One Virtual Investor Forum
pharmiweb.com - April 8 at 9:12 AM
Arix portfolio firm Artios Pharma to collaborate with Novartis on cancer therapy developmentArix portfolio firm Artios Pharma to collaborate with Novartis on cancer therapy development
proactiveinvestors.co.uk - April 7 at 8:35 AM
Arix Bioscience PLC: Artios announces collaboration with Novartis to create next generation DDR cancer therapiesArix Bioscience PLC: Artios announces collaboration with Novartis to create next generation DDR cancer therapies
finanznachrichten.de - April 7 at 8:35 AM
Arix Bioscience PLC : Arix leads $152 million Series B financing for Pyxis OncologyArix Bioscience PLC : Arix leads $152 million Series B financing for Pyxis Oncology
markets.businessinsider.com - March 31 at 1:55 PM
DateCompanyBrokerageAction
5/13/2021IMVRaymond JamesReiterated Rating
5/13/2021IMVNational Bank FinancialLower Price Target
5/13/2021IMVNational BanksharesLower Price Target
3/18/2021IMVLeede Jones GabReiterated Rating
3/31/2020IMVB. RileyDowngrade
11/26/2019IMVOppenheimerSet Price Target
3/25/2019IMVHC WainwrightReiterated Rating
12/13/2018IMVEchelon Wealth PartnersReiterated Rating
6/19/2018IMVDawson JamesReiterated Rating
6/5/2018IMVMackieBoost Price Target
5/14/2021Decibel TherapeuticsSVB LeerinkLower Price Target
3/15/2021Decibel TherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
3/15/2021Decibel TherapeuticsBarclaysInitiated Coverage
3/15/2021Decibel TherapeuticsBMO Capital MarketsInitiated Coverage
12/4/2020Neptune Wellness SolutionsAlliance Global PartnersLower Price Target
5/17/2020Neptune Wellness SolutionsCowenBoost Price Target
4/26/2021Arix BioscienceShore CapitalReiterated Rating
4/11/2019Arix BioscienceStifel NicolausReiterated Rating
3/29/2019Arix BioscienceJefferies Financial GroupLower Price Target
(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.